Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
Despite remarkable progress in therapeutic options for the management of bladder cancer, it remains a challenge for urologists to achieve successful outcomes in the treatment of both superficial and invasive bladder cancers. In this review, recent advances in the field of antisense oligodeoxynucleotide therapy targeting several genes playing functionally important roles in the progression and recurrence of bladder cancer are summarized. Data showing the synergistic antitumor activities of antisense oligodeoxynucleotide therapy, combined with several treatments, including cytotoxic chemotherapy, radiation and other molecular targeting therapies, are also presented. Finally, the future direction of antisense oligodeoxynucleotide therapy in the therapeutic strategy of bladder cancer is discussed. These findings may help clarify the significance of antisense oligodeoxynucleotide therapy as an attractive alternative to conventional strategies.
Miyake
Hideaki
H
Department of Urology, Hyogo Medical Center for Adults, Akashi 673-8558, Japan. hideakimiyake@hotmail.com
Hara
Isao
I
Fujisaw
Masato
M
Gleave
Martin E
ME
D002986:Clinical Trials as Topic; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D016376:Oligonucleotides, Antisense